Using High-Dose Sufentanil Intrathecally For Painless Induction And Postoperative Pain Management In Gastrointestinal Cancer Surgeries

Background: Intrathecal opioids have demonstrated efficacy in pain management during and after surgery, necessitating further exploration across various surgical procedures. This study examines the use of higher doses of intrathecal synthetic opioids (Sufentanil) for pain control in gastrointestinal cancer surgeries, highlighting the need for additional research to establish conclusive outcomes. Methods: A single-center clinical trial with a control group was conducted, involving adult non-addicted individuals eligible for gastrointestinal cancer surgeries. The intervention group (n=۲۵) received intrathecal Sufentanil (۰.۲ mcg/kg) before anesthesia induction, while the control group (n=۲۵) received intravenous Sufentanil (۰.۳ mcg/kg) at induction. The variables between the two groups were compared using chi-square tests, independent t-tests, and exact tests. Results: The average age in the intrathecal group was ۵۵.۱ years ± ۹.۳, and in the intravenous administration group was ۵۴.۲ years ± ۱۳.۲, showing no significant difference (p=۰.۴). A higher proportion of patients in the intrathecal group required three analgesic doses (۵۲%) compared to the IV group, where ۴۴% needed four doses during surgery, with no significant variance observed between groups (p=۰.۳). Postoperative pain scores were lower in the intrathecal group than in the intravenous administration group (۰.۸ ± ۱.۷ vs ۰.۶۶ ± ۵.۱۲, p<۰.۰۰۱). Conclusion: Based on our study findings, Intrathecal Sufentanil at a dose of ۰.۲ mcg/kg reduces postoperative pain by one-third compared to IV administration in gastrointestinal cancer surgeries.

کلیدواژه ها:

Gastrointestinal cancer ، Intrathecally ، Pain ، Sufentanil